The CoClarity Trial, UK Version 1 (9 December 2025)
Research type
Research Study
Full title
Reconsidering Antithrombotic Therapy in patients with advanced cancer using the CoClarity shared decision support tool – The CoClarity Trial
IRAS ID
359951
Contact name
Simon Noble
Contact email
Sponsor organisation
Leiden University Medical Center
Clinicaltrials.gov Identifier
NL-OMON57960, International Clinical Trials Registry Platform
Duration of Study in the UK
1 years, 8 months, 30 days
Research summary
For some patients with advanced cancer, medicine given to thin the blood can have some negative effects such as bleeding which can impact upon quality of life and wellbeing. However, stopping medication to thin the blood can increase risk for developing a blood clot and/or stroke. There may come a time for some patients where stopping blood thinning medication becomes an option and they can be involved in a conversation with their doctor about the potential risks and benefits of continuing or stopping blood thinning medication and make a shared decision with their doctor about whether they want to stop or continue.
This study is part of a wider programme of work being done in a number of European countries to develop and evaluate an online decision support tool to help future patients with cancer make choices about continuing or stopping this medicine in partnership with their doctors. The online tool will provide patients with information about continuing or stopping blood thinning medication (antithrombotic therapy), what the risks and benefits might be and help them think about what matters most to them in the decision.
The decision support tool is called CoClarity and a training package for clinicians has also been developed. Together these form a complex intervention which will be evaluated within this cluster randomised trial.REC name
Wales REC 6
REC reference
26/WA/0077
Date of REC Opinion
7 Apr 2026
REC opinion
Further Information Favourable Opinion